Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Extracellular Vesicle Quantification and Characterization: Common Methods and Emerging Approaches.

Hartjes TA, Mytnyk S, Jenster GW, van Steijn V, van Royen ME.

Bioengineering (Basel). 2019 Jan 16;6(1). pii: E7. doi: 10.3390/bioengineering6010007. Review.

2.

Epithelial-Mesenchymal Transition in Human Prostate Cancer Demonstrates Enhanced Immune Evasion Marked by IDO1 Expression.

Kolijn K, Verhoef EI, Smid M, Böttcher R, Jenster GW, Debets R, van Leenders GJLH.

Cancer Res. 2018 Aug 15;78(16):4671-4679. doi: 10.1158/0008-5472.CAN-17-3752. Epub 2018 Jun 19.

PMID:
29921693
3.

Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680-7.

Del Re M, Biasco E, Crucitta S, Derosa L, Rofi E, Orlandini C, Miccoli M, Galli L, Falcone A, Jenster GW, van Schaik RH, Danesi R.

Eur Urol. 2018 Jan;73(1):e11-e12. doi: 10.1016/j.eururo.2017.07.034. Epub 2017 Aug 9. No abstract available.

PMID:
28801127
4.

The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients.

Del Re M, Biasco E, Crucitta S, Derosa L, Rofi E, Orlandini C, Miccoli M, Galli L, Falcone A, Jenster GW, van Schaik RH, Danesi R.

Eur Urol. 2017 Apr;71(4):680-687. doi: 10.1016/j.eururo.2016.08.012. Epub 2016 Oct 10.

PMID:
27733296
5.

The Potential of MicroRNAs as Prostate Cancer Biomarkers.

Fabris L, Ceder Y, Chinnaiyan AM, Jenster GW, Sorensen KD, Tomlins S, Visakorpi T, Calin GA.

Eur Urol. 2016 Aug;70(2):312-22. doi: 10.1016/j.eururo.2015.12.054. Epub 2016 Jan 22. Review.

6.

Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells.

Onstenk W, Sieuwerts AM, Kraan J, Van M, Nieuweboer AJ, Mathijssen RH, Hamberg P, Meulenbeld HJ, De Laere B, Dirix LY, van Soest RJ, Lolkema MP, Martens JW, van Weerden WM, Jenster GW, Foekens JA, de Wit R, Sleijfer S.

Eur Urol. 2015 Dec;68(6):939-45. doi: 10.1016/j.eururo.2015.07.007. Epub 2015 Jul 15.

PMID:
26188394
7.

MiR-1247-5p is overexpressed in castration resistant prostate cancer and targets MYCBP2.

Scaravilli M, Porkka KP, Brofeldt A, Annala M, Tammela TL, Jenster GW, Nykter M, Visakorpi T.

Prostate. 2015 Jun;75(8):798-805. doi: 10.1002/pros.22961. Epub 2015 Mar 1.

PMID:
25731699
8.

A 36-gene signature predicts clinical progression in a subgroup of ERG-positive prostate cancers.

Gasi Tandefelt D, Boormans JL, van der Korput HA, Jenster GW, Trapman J.

Eur Urol. 2013 Dec;64(6):941-50. doi: 10.1016/j.eururo.2013.02.039. Epub 2013 Mar 7.

PMID:
23490727

Supplemental Content

Loading ...
Support Center